AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34794202 — intervention group
Group type: EXPERIMENTAL
Intervention: CitruSlim low-dose (LD, 200 mg)
Number of subjects: 97
Study 34794202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 33836627 — intervention group
Group type: EXPERIMENTAL
Intervention: DigiKnowIt News (interactive, multimedia educational website)
Number of subjects: 91
Study 33836627 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no access to DigiKnowIt News during the study)
Number of subjects: 91
Study 33221203 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand with the fewest ingredients
Number of subjects: 722
Study 33221203 — intervention group
Group type: COMPARATOR
Intervention: Other two brands of wipes
Number of subjects: 722
Study 32568642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 932
Study 32568642 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 932
Study 36357712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 0
Study 36357712 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 34154636 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale drinking water supply intervention
Number of subjects: 280000
Study 32490740 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 32490740 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with UTI
Number of subjects: 75
Study 32490740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystitis group
Number of subjects: 75
Study 32490740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyelonephritis group
Number of subjects: 75
Study 35181113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabernet Sauvignon wines with origin information
Number of subjects: 112
Study 35181113 — intervention group
Group type: COMPARATOR
Intervention: Cabernet Sauvignon wines without origin information
Number of subjects: 112
Study 34412705 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group (INT) - physical exercise training programme at moderate-to-vigorous intensity, 1 h three times weekly for 8 weeks
Number of subjects: 25
Study 34412705 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - encouraged to continue usual level of activity, offered training programme after 8 weeks
Number of subjects: 25
Study 36270584 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hepatic inflow occlusion (TIO)
Number of subjects: 258
Study 36270584 — intervention group
Group type: COMPARATOR
Intervention: Hemihepatic inflow occlusion (HIO)
Number of subjects: 258
Study 34694750 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastinated models
Number of subjects: 96
Study 34694750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed models
Number of subjects: 96
Study 34694750 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey instrument
Number of subjects: 96
Study 35299288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat plus isosorbide mononitrate
Number of subjects: 41
Study 35299288 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus isosorbide mononitrate
Number of subjects: 41
Study 32128865 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Reminder System based on the Health Belief Model (CRS‐HBM)
Number of subjects: 174
Study 35657540 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastibell device (PD)
Number of subjects: 206
Study 35657540 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenular artery preservation (FAP)
Number of subjects: 206
Study 35657540 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenular artery ligation (FAL)
Number of subjects: 206
Study 32443348 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block with periarticular infiltration (30 mL of 0.5% ropivacaine and 100 mcg of clonidine)
Number of subjects: 0
Study 32443348 — intervention group
Group type: COMPARATOR
Intervention: Periarticular infiltration alone
Number of subjects: 0
Study 35290169 — intervention group
Group type: EXPERIMENTAL
Intervention: Gimsilumab
Number of subjects: 225
Study 35290169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 32856870 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Energy Techniques (METS)
Number of subjects: 48
Study 32856870 — intervention group
Group type: COMPARATOR
Intervention: Active Range of Motion Exercises (AROM)
Number of subjects: 48
Study 35481557 — intervention group
Group type: EXPERIMENTAL
Intervention: 5μT low-frequency electromagnetic field (LF-EMF) signal for 30 minutes
Number of subjects: 32
Study 35481557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 32
Study 32638023 — intervention group
Group type: EXPERIMENTAL
Intervention: Children HIV-exposed uninfected (CHEU)
Number of subjects: 428
Study 32638023 — intervention group
Group type: COMPARATOR
Intervention: Children HIV-unexposed uninfected (CHUU)
Number of subjects: 428
Study 32638023 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEU
Number of subjects: 428
Study 32638023 — intervention group
Group type: COMPARATOR
Intervention: CHEU vs CHUU
Number of subjects: 428
Study 33896333 — intervention group
Group type: EXPERIMENTAL
Intervention: M7583 at 80 mg (three days)/160 mg (full 28-day cycle), then 300 mg/day, 600 mg/day, 900 mg/day, and 300 mg twice daily
Number of subjects: 18
Study 33896333 — intervention group
Group type: EXPERIMENTAL
Intervention: M7583
Number of subjects: 18
Study 34124987 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythropoietin (3000 IU/mL) four times a day
Number of subjects: 8
Study 34716710 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogic book‐sharing (8 weekly group sessions)
Number of subjects: 140
Study 34716710 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 140
Study 32403918 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Natural Cycle (mNC)
Number of subjects: 129
Study 32403918 — intervention group
Group type: COMPARATOR
Intervention: Artificial Cycle (AC)
Number of subjects: 129
Study 32403918 — intervention group
Group type: COMPARATOR
Intervention: Natural Cycle (NC)
Number of subjects: 129
Study 34067295 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 20
Study 34067295 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study 32111767 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention
Number of subjects: 537
Study 34839016 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus bevacizumab
Number of subjects: 155
Study 34839016 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib alone
Number of subjects: 155
Study 34172060 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased written health education combined with healthy diet
Number of subjects: 130
Study 34172060 — intervention group
Group type: COMPARATOR
Intervention: Routine health education
Number of subjects: 130
Study 32585261 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic activation
Number of subjects: 80
Study 32585261 — intervention group
Group type: EXPERIMENTAL
Intervention: XP‐endo Finisher files
Number of subjects: 80
Study 32585261 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐file activation
Number of subjects: 80
Study 32585261 — intervention group
Group type: COMPARATOR
Intervention: Needle irrigation
Number of subjects: 80
Study 35849545 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal wavefront-guided transPRK (CWFG)
Number of subjects: 71
Study 35849545 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized transPRK (WFO)
Number of subjects: 71
Study 33878282 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing anticholinergic medications (ACM) over 1 to 6 months with education directed at psychiatrists and clinical pharmacy support.
Number of subjects: 0
Study 33878282 — intervention group
Group type: COMPARATOR
Intervention: Restarting ACM for re-emergent EPS.
Number of subjects: 0
Study 32527232 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (loading dose of 1.25 mg, followed by 0.625 mg every 8 hours for 5 days)
Number of subjects: 306
Study 32527232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 32527232 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 306
Study 34662000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (80 mg daily)
Number of subjects: 50
Study 34662000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32770409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce Back intervention
Number of subjects: 326
Study 32770409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce Back intervention (moderate compliance)
Number of subjects: 326
Study 32770409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce Back intervention (high compliance)
Number of subjects: 326
Study 32770409 — intervention group
Group type: COMPARATOR
Intervention: Control group (practice as usual)
Number of subjects: 326
Study 33216791 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred, risk-guided approach to addressing risks identified via risk assessment during pregnancy (9 practices)
Number of subjects: 1579
Study 33216791 — intervention group
Group type: COMPARATOR
Intervention: Usual care (7 practices)
Number of subjects: 1579
Study 35291004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (30 mg/kg) and ethambutol (R30HZE)
Number of subjects: 37
Study 35291004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin and levofloxacin (R30HZL)
Number of subjects: 37
Study 35291004 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rifampicin and ethambutol (R15HZE)
Number of subjects: 37
Study 34215198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 110
Study 34215198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 110
Study 34651349 — intervention group
Group type: EXPERIMENTAL
Intervention: APF + FGG
Number of subjects: 49
Study 34651349 — intervention group
Group type: COMPARATOR
Intervention: APF + CM
Number of subjects: 49
Study 34156917 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 249
Study 34156917 — intervention group
Group type: COMPARATOR
Intervention: Physiologically predicted 'poor' adherence
Number of subjects: 249
Study 34156917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower arousal threshold (ArTH)
Number of subjects: 249
Study 34156917 — intervention group
Group type: EXPERIMENTAL
Intervention: High and low pharyngeal muscle compensation (Vcomp)
Number of subjects: 249
Study 35131823 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-PBT (perturbation-based balance training)
Number of subjects: 140
Study 35131823 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 140
Study 34534800 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day internet-based cognitive behavioral therapy (CBT)
Number of subjects: 16
Study 34432514 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (0.1 mg/kg, IM) alone (group H)
Number of subjects: 39
Study 34432514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.1 mg/kg, IM) with acepromazine (0.05 mg/kg, IM; group AH)
Number of subjects: 39
Study 34432514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.1 mg/kg, IM) with dexmedetomidine (6 µg/kg, IM; group DH)
Number of subjects: 39
Study 34432514 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (group H)
Number of subjects: 39
Study 34432514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone with acepromazine (group AH)
Number of subjects: 39
Study 34053974 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct technique with Clearfil DC Core (DC)
Number of subjects: 0
Study 34053974 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect technique with Clearfil DC Core (DC)
Number of subjects: 0
Study 34053974 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct technique with Panavia V5 (PV)
Number of subjects: 0
Study 34053974 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect technique with Panavia V5 (PV)
Number of subjects: 0
Study 35230749 — intervention group
Group type: EXPERIMENTAL
Intervention: GP40071 (GP‐Asp)
Number of subjects: 26
Study 35230749 — intervention group
Group type: COMPARATOR
Intervention: NovoRapid Penfill (Novo‐Asp)
Number of subjects: 26
Study 35230749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GP40071 and NovoRapid
Number of subjects: 26
Study 35020025 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-only stabilization
Number of subjects: 58
Study 35020025 — intervention group
Group type: COMPARATOR
Intervention: Global reconstruction through a single-stage all-posterior approach
Number of subjects: 58
Study 33025002 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 27347
Study 33025002 — intervention group
Group type: COMPARATOR
Intervention: Estrogens plus medroxyprogesterone acetate
Number of subjects: 27347
Study 34491225 — intervention group
Group type: EXPERIMENTAL
Intervention: Guppy fish, Pyriproxyfen (PPF), and Communication for Behavioral Impact (COMBI)
Number of subjects: 30
Study 34491225 — intervention group
Group type: EXPERIMENTAL
Intervention: Guppy fish and COMBI
Number of subjects: 30
Study 34491225 — intervention group
Group type: COMPARATOR
Intervention: Control (standard vector control)
Number of subjects: 30
Study 33792958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg/d)
Number of subjects: 81
Study 33792958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 33268419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous zinc (0.5 mg/kg)
Number of subjects: 160
Study 33268419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 36336851 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid irrigation
Number of subjects: 222
Study 36336851 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 222
Study 36336851 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 222
Study 36336851 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid irrigation, Saline irrigation, No treatment
Number of subjects: 222
Study 33441103 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 0
Study 35264692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichoptic movies (3 movies/week)
Number of subjects: 65
Study 35264692 — intervention group
Group type: COMPARATOR
Intervention: Patching (14 hours/week)
Number of subjects: 65
Study 32273682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg kg‐1
Number of subjects: 133
Study 32273682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 133
Study 32273682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg kg‐1
Number of subjects: 133
Study 32273682 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline values at T0)
Number of subjects: 133
Study 34718462 — intervention group
Group type: EXPERIMENTAL
Intervention: POC EID (onsite testing with the Alere q HIV‐1/2 Detect)
Number of subjects: 4000
Study 34718462 — intervention group
Group type: COMPARATOR
Intervention: SOC EID (off‐site testing at a public laboratory)
Number of subjects: 4000
Study 35603904 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident HPV infections
Number of subjects: 20529
Study 35603904 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinogenic HPV types
Number of subjects: 20529
Study 35603904 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncarcinogenic HPV types
Number of subjects: 20529
Study 35603904 — intervention group
Group type: EXPERIMENTAL
Intervention: All HPV types within each study cohort
Number of subjects: 20529
Study 33827848 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model including demographics, comorbidities, laboratory results, and vital signs
Number of subjects: 17086
Study 33827848 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including all demographics and comorbidities
Number of subjects: 17086
Study 33827848 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including only age
Number of subjects: 17086
Study 33827848 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted mortality for patients aged 18 years
Number of subjects: 17086
Study 33827848 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted mortality for patients aged 55 years
Number of subjects: 17086
Study 33827848 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted mortality for patients aged 85 years
Number of subjects: 17086
Study 33827848 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted mortality across all ages over the study period
Number of subjects: 17086
Study 32713395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal whey protein ingestion (63 g whey protein)
Number of subjects: 15
Study 32713395 — intervention group
Group type: COMPARATOR
Intervention: Control (water only)
Number of subjects: 15
Study 35738686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for perfectionism
Number of subjects: 40
Study 35738686 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study 32303839 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy (LM)
Number of subjects: 43
Study 32303839 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilatation (PD)
Number of subjects: 43
Study 32303839 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 43
Study 34816612 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 9)
Number of subjects: 28
Study 34816612 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT; n = 9)
Number of subjects: 28
Study 34816612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT; n = 10)
Number of subjects: 28
Study 32080310 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 21
Study 32080310 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 21
Study 35260901 — intervention group
Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life (RCL) Teenage Pregnancy Prevention program
Number of subjects: 518
Study 33089669 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding disorders (identified using the DVISS scale with a score of 8.5 or above)
Number of subjects: 907
Study 33089669 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-time urinary incontinence
Number of subjects: 907
Study 33089669 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time incontinence
Number of subjects: 907
Study 33089669 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related prevalence
Number of subjects: 907
Study 33089669 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of voiding disorders
Number of subjects: 907
Study 33089669 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 907
Study 35213246 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole and praziquantel
Number of subjects: 60
Study 35213246 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 60
Study 35213246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34598983 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded music through overear headphones before, during, and after surgery until postoperative day 3.
Number of subjects: 0
Study 34598983 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (control group).
Number of subjects: 0
Study 35279338 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom group (alternative drugs based on pharmacogenetic testing)
Number of subjects: 107
Study 35279338 — intervention group
Group type: COMPARATOR
Intervention: Control group (oxycodone, tramadol, and celecoxib)
Number of subjects: 107
Study 35639969 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI-Motivate scores
Number of subjects: 371
Study 35639969 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI-Barrier subscores
Number of subjects: 371
Study 34452970 — intervention group
Group type: EXPERIMENTAL
Intervention: CORKA (Community Rehabilitation after Knee Arthroplasty) home‐based rehabilitation, receiving a median five treatment sessions (IQR 4‐7)
Number of subjects: 621
Study 34452970 — intervention group
Group type: COMPARATOR
Intervention: Usual care outpatient physiotherapy, receiving a median 4 sessions (IQR 2‐6)
Number of subjects: 621
Study 34452970 — intervention group
Group type: EXPERIMENTAL
Intervention: CORKA home‐based rehabilitation
Number of subjects: 621
Study 34452970 — intervention group
Group type: COMPARATOR
Intervention: Usual care outpatient physiotherapy
Number of subjects: 621
Study 32516395 — intervention group
Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer
Number of subjects: 40
Study 32516395 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro White Varnish
Number of subjects: 40
Study 32516395 — intervention group
Group type: EXPERIMENTAL
Intervention: Shield Force Plus
Number of subjects: 40
Study 32516395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 40
Study 36327275 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous butylscopolamine bromide
Number of subjects: 250
Study 36327275 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (1 mL sodium chlorine 9 mg/mL)
Number of subjects: 250
Study 32634291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnoea
Number of subjects: 276
Study 32634291 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 276
Study 32634291 — intervention group
Group type: EXPERIMENTAL
Intervention: Restless legs
Number of subjects: 276
Study 32634291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightmares
Number of subjects: 276
Study 32125929 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRIPLA + rosemary aqueous extract (4 g/L per day)
Number of subjects: 67